Acumen Pharmaceuticals Inc.

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Frequently asked questions
To buy Acumen Pharmaceuticals Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Acumen Pharmaceuticals Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Acumen Pharmaceuticals Inc. is ABOS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Acumen Pharmaceuticals Inc. has its primary listing on NASDAQ. You can trade Acumen Pharmaceuticals Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Acumen Pharmaceuticals Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Acumen Pharmaceuticals Inc. as part of a broader investment portfolio.